4DMT Announces Promising Financial Results and Key Clinical Developments
March 1, 2025 - 00:01
4DMT has reported encouraging interim data from its ongoing clinical trials, showcasing significant advancements in its treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The results from the PRISM Phase 1/2 trial for 4D-150 indicate robust and durable clinical activity across a diverse patient population, with a favorable tolerability profile observed over a 52-week period and beyond.
In addition to the AMD findings, the company also revealed positive interim results from the SPECTRA clinical trial, specifically from Part 1, which focuses on DME. These 32-week data results are pivotal as they demonstrate the potential effectiveness of 4D-150 in treating this condition.
Moreover, 4DMT has achieved alignment with the FDA regarding its development strategy, indicating that a single Phase 3 trial could be sufficient for a Biologics License Application (BLA) submission for 4D-150 in DME, especially when combined with data from the 4FRONT study. This strategic direction marks a significant milestone for the company as it seeks to advance its therapeutic offerings in the ophthalmology space.
MORE NEWS
June 18, 2026 - 00:10
Chairman Kevin Warsh: Financial markets work less efficiently when they consider what Fed thinksFederal Reserve Chairman Kevin Warsh argued on Wednesday that financial markets become less efficient when traders and investors spend too much time guessing what the central bank will do next....
June 17, 2026 - 02:28
City Council rejects first reading of budget, amendment approved to finance Ajax Turner non-profitThe City Council held its second first reading of the Fiscal Year budget on Tuesday night, but the outcome mirrored the previous session. Despite cutting more than $697,000 in proposed spending,...
June 16, 2026 - 22:13
'El Jefe' speaks: forget about 2008, it's really more like 2004The most senior chief financial officer among New York-listed companies has a message for investors who are bracing for a repeat of the 2008 financial crisis: calm down. According to the executive,...
June 16, 2026 - 07:40
RBA interest rate decision live: Aussies 'forced into hibernation' brace for year of painThe Reserve Bank of Australia has announced its latest cash rate decision, keeping interest rates on hold at 4.35 percent. The move was widely expected by economists, but it offers little relief...